Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab

Ann Oncol. 2017 Dec 1;28(12):3106-3107. doi: 10.1093/annonc/mdx497.

Authors

K Otsubo¹, K Nakatomi¹, R Furukawa¹, K Ashida², Y Yoneshima¹, Y Nakanishi¹, I Okamoto¹

Affiliations

¹ Research Institute for Diseases of the Chest.
² Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

PMID: 28945828
DOI: 10.1093/annonc/mdx497

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / immunology
Adenocarcinoma / surgery
Adenocarcinoma of Lung
Adrenal Insufficiency / chemically induced*
Adrenal Insufficiency / immunology
Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / immunology
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / immunology
Clinical Trials, Phase III as Topic
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / immunology
Lung Neoplasms / surgery
Male
Nivolumab
Randomized Controlled Trials as Topic
Substance Withdrawal Syndrome / etiology*
Substance Withdrawal Syndrome / immunology

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Nivolumab